



# AstraZeneca in the US

Pioneering science & economic growth





# Contents

3	AstraZeneca in the United States
4	Contributing to the US Economy
6	Exporting across the globe
7	Cutting edge Research & Development
10	Improving health outcomes through collaboration
13	Developing industry leaders of the future
16	Supporting our communities
18	Sustainability
21	Methodology





# AstraZeneca in the United States

At AstraZeneca, we believe in the power of what science can do. As a global, science-led biopharmaceutical company, AstraZeneca is focused on the discovery, development and commercialization of medicines for millions of patients worldwide.

Empowered by digital, data and AI, pioneering science is accelerating our understanding of disease, helping us better predict clinical success and deliver life-changing medicines to help people with chronic diseases live better, healthier lives, redefine cancer care, and pioneer treatments for rare diseases.

As our largest market, representing over 40% of our business today and half by the end of the decade, the United States (US) plays an important role in our ability to deliver on our 2030 ambition to launch 20 new medicines and be an \$80 billion company. To support that ambition, we have invested billions of dollars to grow our presence, manufacturing capacity and scientific capabilities across the US, building on our expansive commercial, manufacturing and research and development (R&D) footprint that includes:

- One of six strategic R&D centers in Gaithersburg, MD, with over 4,500 employees, and world-class laboratories benefiting from over \$1 billion in annual R&D spending.
- A future strategic R&D center in Kendall Square, the life science ecosystem hub in Boston, MA, which will house approximately 1,850 employees and is designed to encourage collaboration and innovation.
- Our commercial business headquarters in Wilmington, DE, home to our US BioPharmaceuticals Business Unit and several integral functions, which employs over 1,200 employees in total.
- 11 manufacturing sites across eight states and Puerto Rico, including our newest cell therapy facility in Rockville, MD, employing more than 4,000 people combined.

In July 2025, we announced \$50 billion of investment in the US by 2030, building on America's global leadership in medicines manufacturing and R&D. The cornerstone of this landmark investment is a new multi-billion dollar US manufacturing facility, planned to be in the Commonwealth of Virginia.

## In the US, in 2024, AstraZeneca:



Contributed \$5 billion directly to the economy, and created approximately \$20 billion worth of overall value for the American economy



Directly employed over 18,000 people: 20% of our total employee population



Supported 92,000 jobs across the economy



Treated over 9 million patients with our medicines



Exported \$5 billion of American-made medicines across the globe



Spent \$4.6 billion on R&D by US-based teams




Fostered progress in healthcare through close to 800 partnerships with academia and industry



Provided over 250 internships across our sites




Contributed over 9,000 volunteer hours to community initiatives impacting 40,000 lives





# AstraZeneca's economic contribution in the United States



In 2024, AstraZeneca contributed \$5 billion directly to the US economy<sup>1</sup> and employed 18,000 people across all sites. Taking into account our extensive supply chains in the US, we created approximately \$20 billion of economic value and supported 92,000 jobs across the country.

In other words, for every colleague in AstraZeneca, four jobs are supported elsewhere across the US.

The average AstraZeneca employee directly adds close to \$300,000 to the US economy each year, around twice as much as the average American worker, contributing to a high-productivity, high-wage economy.

That includes supporting high-quality employment in the manufacturing sector, where we are expanding our operations. Our new \$300 million facility in Rockville, MD - unveiled in 2025 - will be central to AstraZeneca's production of next-generation cell therapies and brings our number of US manufacturing sites up to 11.

<sup>1</sup> Measured in terms of gross value added (GVA)



## Manufacturing innovative medicines in Mount Vernon

AstraZeneca's Mount Vernon, Indiana, site has been a major economic contributor to the Southwest Indiana community for years, with over 700 employees working to manufacture our life-saving medications for diabetes, cardiovascular and cancer patients around the world. Our Mount Vernon facility is our largest in the US that makes oral solid dose tablets - 5.6 billion in 2024.

That includes manufacturing about half of our global production for one of our cardiovascular, renal and metabolic medicines.

The Mount Vernon site is also industry-leading when it comes to energy efficiency, recently earning the US Environmental Protection Agency's (EPA's) ENERGY STAR certification, which signifies that the industrial plant performs in the top 25% of similar facilities nationwide for energy efficiency and meets strict performance levels set by the EPA. This has been achieved through significant investment in the plant, including replacing nearly 100,000 lamps to save energy, utilizing smart energy usage technologies and installing a 3.5-megawatt solar field, which offsets approximately 15% of our site's total purchased electricity.



Mount Vernon, IN



# American-made medicines, exported across the globe




**Pharmaceuticals are a major exporting industry for the US, ranking as the third largest goods export category in 2024.** Pharmaceutical exports reached \$108 billion, marking a 6.6% increase compared to 2023. This growth rate was three times higher than the overall export growth for the US economy.<sup>2</sup>



**AstraZeneca plays a key role in supporting this export success story. Last year, our American-made medicines exported totaled \$5 billion – or about 5% of all American pharmaceutical exports.**



**Our largest US export markets in 2024 included the United Kingdom (\$1 billion of exports), China (also \$1 billion) and Japan (close to \$600 million).** Our US-made medicines have treated millions of patients across the Americas, Europe, Asia, Africa and Oceania.



AstraZeneca US medicines exported across the globe, US dollars

<sup>2</sup> *International Trade in Goods and Services*, Bureau of Economic Analysis, 2025. Available at: <https://www.bea.gov/data/intl-trade-investment/international-trade-goods-and-services>





# Cutting Edge Research & Development

Finding new cures and treatments can only be achieved with sustained investment in R&D.

AstraZeneca is among the leading industry investors in R&D globally, and we are investing in transformative new technologies and modalities that will shape the future of medicine and sustain our growth post-2030.

**In 2024 alone, our US teams invested \$4.6 billion in R&D.** That includes \$1.6 billion on rare disease and chronic disease research, and \$1.4 billion on research into new cancer treatments.

It also includes \$1.5 billion of investment into clinical trials to test emerging treatments and therapies. **In 2024, over 10,800 patients were enrolled in 216 AstraZeneca-sponsored clinical trials**, spanning a range of treatment areas.

## Our investment in transformative R&D technologies includes:




**Antibody drug conjugates and radioconjugates** that aim to replace systemic chemotherapy and radiotherapy



**Cell therapy and T-cell engagers** that are more scalable across therapy areas




**Gene therapy and gene editing** that could make cures possible for a range of rare diseases



Next-generation **immuno-oncology bispecifics** that establish new immuno-oncology segments




**Weight management** that looks beyond short-term weight loss to address individual patient needs




**71**  
BioPharmaceutical trials




**130**  
Oncology trials



**15**  
Rare disease trials





**“We know that the next generation of therapeutics must go beyond traditional treatments to address the unmet needs of patients. Our innovative approach to research and development aims to deliver the quickest and greatest impact possible on disease prevention and treatment without compromising patient care. Science isn’t just what we do, it’s who we are. And we’re unlocking what’s next to transform lives”**

**Joris Silon**

US Country President





## Our two strategic R&D centers in the US - Gaithersburg & Boston

Two of our six global strategic R&D centers are based in the US.


Our scientific campus in Gaithersburg, Maryland, employs more than 4,500 experts pushing the boundaries of science and seeking treatments for a wide range of conditions. With 1.3 million square feet of offices, labs and manufacturing facilities, the campus has the capacity to discover, develop, manufacture, and commercialize life-changing medicines – all on one site.

Employee interaction and wellbeing are built into the campus, with activity-based workspaces, EV charging stations, an on-site Employee Health and Wellness center providing primary care services, and a 10,000+ square foot fitness center. It is also highly sustainable, integrating energy improvement strategies into our facilities, operations, design, and procurement practices through the ISO 50001 Energy Management System.

Opening in 2026, our new global strategic R&D site in Cambridge, Massachusetts, will be at the heart of the greater Boston life science ecosystem in Kendall Square, supporting approximately 1,850 R&D, commercial and corporate colleagues in 570,000 square feet of new space.

The 16-story building will include 10 dedicated lab floors and was designed to foster collaboration and innovation.

Combined with the 2024 opening of Alexion's genomic medicine facility in Kendall Square, and the retention of the Alexion offices in Boston's Seaport, this growing presence underpins our commitment to the Greater Boston area.





# Improving health outcomes through collaboration

Our purpose is to push the boundaries of science to deliver life-changing medicines. We can't do this alone. We partner with academia, governments, peer companies, biotechs, scientific organizations and patient groups to access the best science, stimulate innovation and accelerate delivery of new medicines to target unmet medical need.

In 2024, we had:



Close to

**450**

**partnerships with  
academic institutions**



Over

**330**

**industry collaborations  
across the US**





## The AIRE Mobile Unit

**Our belief in the value of partnerships is what drove us to create the AIRE Mobile Unit** – a unique collaboration among industry peers, grassroots communities and our own employee network – to address a key issue in healthcare: broader access to clinical trials.

### Through partnering with:

**IQVIA** - the leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry.

**BusTest Express** - a nationally recognized leader in mobile health and wellness solutions.

**Walgreens** - a leading pharmacy chain with more than 8,500 store locations throughout the US

### We have:

Reached more than

**640,000**

people through local engagement with our AIRE Mobile Unit - our mobile “clinic on wheels”.

Made more than

**500**

community stops.

Engaged more than

**22,000**

people in clinical trials and disease education while more than 2,100 have been pre-screened for clinical trials.

The full-sized health bus is equipped with exam rooms and staffed with healthcare research professionals who are ready to pre-screen patients and book both an appointment and transportation for patients to visit the clinical trial site they are referred to.

The AIRE Mobile Unit stops in multiple locations within diverse communities across the Los Angeles and San Antonio areas and participates in numerous community events. Volunteers greet visitors, and several bilingual team members - when available - are able to welcome people in languages such as Spanish and Vietnamese, helping to increase engagement with individuals from a variety of backgrounds. AstraZeneca is partnering with local patient and community groups to build trust, foster open communication, and encourage greater participation in clinical trials.





“We knew collaboration would be what set this program apart. By collaborating and harnessing our collective strengths, we can achieve greater success, ultimately benefiting patients.”

Maria Jison

Executive Director Clinical Development  
/ Global Clinical Head at AstraZeneca





# Developing industry leaders of the future

Developing the treatments of the future can only happen if the pharmaceutical industry continues to invest in its workforce. That includes ensuring we are developing talent that meets future skills needs – such as a **growing need for data scientists and artificial intelligence (AI) specialists**. It is estimated that as of now **30% of new drugs will be discovered with the aid of AI**. With this comes huge advantages with **drug discovery timelines potentially reduced by as much as 25-50%**.<sup>3</sup>

To meet these emerging skills needs, AstraZeneca is committed to creating a culture of lifelong learning and development, encouraging employees to build their capabilities in digital literacy, data analytics, enterprise leadership and learning agility. At the same time, the company is investing heavily in early career talent to ensure a pipeline of future life sciences professionals.

## In 2024 we supported:



**Over 250 internships across our US sites**



**55 opportunities through our graduate program**



**55 postdoctoral positions**

We also achieved a significant milestone by registering as a National Apprenticeship Sponsor, enabling deployment of programs across the US. We introduced our first early career apprenticeships, with the launch of our Maintenance Technician and Quality Control Laboratory Technician programs in December 2024.

Our commitment to developing future talent begins with early engagement in education. **AstraZeneca’s science, technology, engineering and math (STEM) programs reached over 40 schools and education institutions in 2024, involving more than 500 of our STEM ambassadors and volunteers.**

<sup>3</sup> *Futureproofing US Pharma Manufacturing Jobs*, The International Society for Pharmaceutical Engineering (ISPE), 2025. Available at: <https://ispe.org/pharmaceutical-engineering/ispeak/futureproofing-us-pharma-manufacturing-jobs>

“As a leading employer and industry innovator, AstraZeneca



is committed to developing the next generation of talent. We are actively partnering with state government, academic institutions, and industry groups to launch apprenticeship programs that build a strong, diverse talent pipeline. These programs will benefit both AstraZeneca and the life sciences sector while creating career pathways for all individuals to grow and thrive in our industry.”

**Brian Stamper**

Executive Director, General Manager, Rockville Manufacturing Center, Cell Therapy Operations





“Through our apprenticeship programs, we’re not only building the right skills and technical knowledge but also building a sustainable talent pipeline that embodies our values and is equipped to drive our bold ambitions forward. Investing in development enables us to grow and retain our talent across our US footprint. Our apprentices are paired with experienced managers and mentors who help participants uncover their strengths, explore career paths, and grow both personally and professionally. The core curriculum is designed to bring our apprentices together, creating a close-knit community that supports continuous learning.”

Monica Marsh

Human Resources Vice President,  
Operations & IT





## Our Summer Internship Program

AstraZeneca's Summer Internship Program is a 10–12-week immersive experience, designed for undergraduate, masters-level and doctoral students. We offer the program across ten of our US sites and, reflecting our diverse skills needs, seek majors across a range of areas: business, supply chain & communications, chemistry & life sciences, engineering, technology & data science, and safety, health & the environment.

Interns work on meaningful projects with real-world impact, helping them to integrate classroom knowledge with practical application in a supportive environment.

The program also offers a range of development opportunities, including workshops from resume writing to LinkedIn branding. Interns benefit from 1:1 career advising, networking events, showcases such as poster day and presentation sessions, and enrichment activities like community service.

“The most satisfying thing for me was the opportunity they gave me to manage projects.



This was a way of them giving me responsibility to see if I could grow from it, which it did! To be able to be the owner of this responsibility gave me a chance to work with others as a leader and grow as a professional.”



Andres

Intern at our Redwood City site



# Supporting our communities

## The Power of Us

Our employee giving program **Power of Us** is designed to support employees across the United States in their volunteer and giving efforts and further cultivate AstraZeneca as a great place to work by connecting employee altruism to our business.

In 2024:



**660 employees volunteered their time**  
to community initiatives  
across the US



**Volunteers committed over 9,100 hours**  
to projects



**More than 270 community causes**  
were supported

Through the power of our people getting out in communities to make a difference, our employees make an exceptional mark – **impacting over 40,000 lives** through giving back activities in 2024.

The Power of Us program also provides a 100% company match to employee donations made towards eligible, recognized charities and nonprofits. Together in 2024, we shared **over \$3.7 million in donations** to the causes that matter most to our employees.

In the same year we provided **\$50 million in corporate donations to nonprofit organizations, supporting charitable causes that impact patients and communities.**





## Advancing health equity

Health begins in our homes, schools and communities, and for too long, systemic barriers have prevented millions of Americans from achieving the best possible health outcomes. This leads to pervasive health inequalities.

AstraZeneca US has made a long-term commitment to identify and invest in community-based solutions addressing health disparities among communities that have experienced barriers to care and opportunity. Through our ACT on Health Equity Community Investment programs, we are continuing to transform the way we do business to improve access, affordability, and outcomes for patients in the disease areas and communities we serve.

Since 2021, over \$3.7 million has reached over 160 awardee organizations as part of our Community Solutions Challenge (CSC). That includes the Parkland Health Foundation, which is providing routine breast cancer screenings in underserved communities to reach high-risk women where they live, work, and learn. Another CSC awardee is Community Savings, Inc., which has delivered over half a million made-from-scratch, medically-tailored meals to the homes of over 3,000 individuals impacted by critical and chronic illnesses.



“In a fast-paced world of science, our efforts in health equity must keep up. Data must be the driving force to change the healthcare sector as a whole and equip us with insights to understand how to reach more people more effectively. The journey toward health equity is ongoing, and by embracing change, we can accelerate a future where healthcare is accessible to all.”

Mohit Manrao

Senior Vice President,  
Head of US Oncology Business  
Unit





# Sustainability

Recognizing the strong connection between business growth and resilience, and the need to address the major health challenges of our time, we deliver sustainable impact through our business. Our commitment to supporting the health of people, society and the planet is vital to our purpose of pushing the boundaries of science to deliver life-changing medicines.

We are working to avoid and eliminate environmental impact throughout the design and development of our medicines. This includes eliminating emissions across our R&D and manufacturing operations and fleet, ensuring more efficient use of water and materials and reducing waste, while growing our business.

**In the United States, from 2015 to the end of 2024, AstraZeneca has:**



## 80%

**Reduced our Scope 1 and 2 greenhouse gas emissions**


by close to 80%, equivalent to 146,000 tons of carbon dioxide. This reduction is comparable to the annual energy usage of close to 20,000 American homes.



## 20%

**Reduced our water use by 20%**

- over 263,000 cubic meters, equivalent to the water usage of over 600 American households.



## 56%

**Transitioned over half (56%) of our corporate vehicle fleet to fully electric.**





“We’re working to improve health outcomes for patients while reducing the environmental footprint of care and are doing so in a way that is underpinned by ethical and value-driven behaviors. The health of the planet is inextricably linked to people’s health, and we need to act together for our children and future generations.”



**Pam Cheng**

Executive Vice President,  
Global Operations and IT &  
Chief Sustainability Officer





## Embedding sustainability in our US R&D centers

Gaithersburg, one of two strategic R&D centers in the US, has operations that span oncology R&D to biologics clinical production. Our Gaithersburg site prides itself on sustainability and by 2026 we anticipate achieving a 98% reduction in scope 1 and 2 greenhouse gas emissions.

Circular economy principles are also embedded at the site, with the majority of medical waste generated from laboratory and manufacturing operations recycled through our partnership with Triumvirate Environmental. Sustainability is also a key consideration at our new strategic R&D center in Boston, opening in 2026. The site aims to have platinum Leadership in Energy & Environmental Design (LEED) certification, the highest level of certification.



## Delivering renewable natural gas to our research and manufacturing sites

In a first-of-its-kind collaboration, AstraZeneca partnered with Vanguard Renewables to enable the delivery of renewable natural gas (RNG) to all of our sites in the United States by the end of 2026.

Since 2023, we have been purchasing RNG produced by Vanguard Renewables for our Newark Campus in Delaware, where we package close to 30 medicines for distribution across the US and make medicine formulations for global supply.

To produce RNG, Vanguard Renewables works with dairy farmers and food and beverage manufacturers to use farm-based anaerobic digestion plants fueled by food and agricultural waste.

By 2026, the collaboration will enable as much as 650,000 million British thermal units (MMBtu), or 190,500 megawatt hours (MWh) per year, of RNG to be used across AstraZeneca's US sites, equivalent to the energy required to heat more than 17,800 US homes for a year.



## Appendix

# Economic impact methodology

---

To value AstraZeneca's direct, supply chain (indirect) and employee spending (induced) economic impacts, Public First drew on detailed "input-output" and "supply-and-use" tables for the US economy published by the Bureau of Economic Analysis.

These tables describe the interrelationships between industry sectors in the economy, and allowed Public First to quantify economic multipliers associated with spending on different goods and services.

Economic multipliers tell us the gains to the economy in monetary and jobs terms as a result of increased spending, including not just direct impacts of such spending but also ripple-through benefits along supply chains and through employee spending.

Public First applied these economic multipliers to internal data provided by AstraZeneca US on its direct financial and employment footprint, and its procurement spending.





 **PUBLIC FIRST**

A SHGH Company

Deep insights. Straight advice. Real results.

August 2025

